Publications
Explore a selection of our publications to date below.
| Title | Journal/Conference | Year | journal_hfilter | test_hfilter | tumor_type_hfilter | biomarker_hfilter | publication_year_hfilter |
|---|---|---|---|---|---|---|---|
| Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients | OncoImmunology | 2020 | oncoimmunology | msi pd-l1-ihc rnaseq tmb | renal-cell-carcinoma | cell-proliferation | 2020 |
| Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity | OncoImmunology | 2020 | oncoimmunology | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-profile | 2020 |
| Distinct pathways of DC-induced CD8+ T cell differentiation revealed by single-cell mRNA sequencing analysis | AACR Annual Meeting 2020 | 2020 | aacr-annual-meeting-2020 | rnaseq | immune-cells | immune-profile | 2020 |
| Single-cell mRNA sequencing analysis of the synergistic impact of double-stranded RNA (dsRNA) and IFNa on human monocyte-derived macrophages | AACR Annual Meeting 2020 | 2020 | aacr-annual-meeting-2020 | rnaseq | immune-cells | immune-profile | 2020 |
| Molecular characterization of advanced muscle invasive bladder cancer (MIBC): Comparison of low-input targeted RNA sequencing (RNAseq) strategies | 2020 Genitourinary Cancers Symposium | 2020 | 2020-genitourinary-cancers-symposium | rnaseq | bladder-cancer | comparator-study | 2020 |
| Inflammation and cell proliferation signatures: Implications for response to immune checkpoint inhibition therapies | 2020 ASCO-SITC Clinical Immuno-Oncology Symposium | 2020 | 2020-asco-sitc-clinical-immuno-oncology-symposium | rnaseq | solid-tumors | cell-proliferation inflammation tumor-immunogenic-signature | 2020 |
| Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer | 2020 ASCO-SITC Clinical Immuno-Oncology Symposium | 2020 | 2020-asco-sitc-clinical-immuno-oncology-symposium | rnaseq | lung-cancer | inflammation tumor-immunogenic-signature | 2020 |
| TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer | Frontiers in Immunology | 2020 | frontiers-in-immunology | tcrb | melanoma | ctla-4 tcr%ce%b2 | 2020 |
| Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay | Oncotarget | 2019 | oncotarget | msi | solid-tumors | analytical-validation | 2019 |
| Unique Tumor Immune Microenvironments Of Potentially PD-L1/TGF-β Trap Responsive Tumors | SITC's 34th Annual Meeting (2019) | 2019 | sitcs-34th-annual-meeting-2019 | msi pd-l1-ihc rnaseq tmb | solid-tumors | bispecifics tme | 2019 |
| CT Antigens are Frequently Expressed in Non-Inflamed Tumors | SITC's 34th Annual Meeting (2019) | 2019 | sitcs-34th-annual-meeting-2019 | msi pd-l1-ihc rnaseq tmb | solid-tumors | ct-antgiens tme | 2019 |
| Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing | Journal of Immunotherapy and Precision Oncology | 2019 | journal-of-immunotherapy-and-precision-oncology | tcrb | peripheral-blood-leukocytes | haplotype-analysis tcr%ce%b2 | 2019 |
| Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC | Journal of Thoracic Oncology | 2019 | journal-of-thoracic-oncology | rnaseq | solid-tumors | bmi immune-profile metformin | 2019 |
| Oncologist uptake of comprehensive genomic profile guided targeted therapy | Oncotarget | 2019 | oncotarget | ocp | solid-tumors | clinical-decision-making clinical-utility | 2019 |
| Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | msi pd-l1-ihc rnaseq tmb | renal-cell-carcinoma | cell-proliferation patient-response tumor-inflammation | 2019 |
| Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC) | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | msi pd-l1-ihc rnaseq tmb | renal-cell-carcinoma | cell-proliferation patient-response tumor-inflammation | 2019 |
| Tumor Mutational Burden (TMB): Assessment of Inter-and Intra-tumor heterogeneity | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | tmb | solid-tumors | comparator-study specimen-characteristics validation | 2019 |
| RNA-sequencing reveals immunotherapy targets in gynecological cancer | ASCO-SITC Clinical Immuno-Oncology Symposium - 2019 | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | msi pd-l1-ihc rnaseq tmb | gynocological-cancers | immune-profile immune-suppression | 2019 |
| Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients | Journal for ImmunoTherapy of Cancer | 2019 | journal-for-immunotherapy-of-cancer | msi pd-l1-ihc rnaseq tmb | non-small-cell-lung-cancer | cell-proliferation patient-survival | 2019 |
| Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors | Journal for ImmunoTherapy of Cancer | 2019 | journal-for-immunotherapy-of-cancer | pd-l1-ihc rnaseq | solid-tumors | comparator-study patient-response pd-l1 | 2019 |
| Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing | BMC Medical Informatics and Decision Making | 2019 | bmc-medical-informatics-and-decision-making | ocp | solid-tumors | clinical-decision-making clinical-utility | 2019 |
| RNA-Expression Profiling Reveals Immunotherapy Targets in Sarcoma | Journal of Sarcoma Research | 2018 | journal-of-sarcoma-research | msi pd-l1-ihc rnaseq tmb | sarcoma | immune-profile myeloid-suppression | 2018 |
| Identification of targets for prostate cancer immunotherapy | The Prostate | 2018 | the-prostate | msi pd-l1-ihc rnaseq tmb | prostate-cancer | immune-profile | 2018 |
| Tumor mutational burden (TMB) ring study: Comparison of multiple targeted next-generation sequencing (NGS) platforms | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | tmb | solid-tumors | comparator-study tmb | 2018 |
| Identifying major immune subsets of GI tumors for clinical purposes | SITC's 33rd Annual Meeting (2018) | 2018 | sitcs-33rd-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | gi-tumors | immune-profile | 2018 |
| Development of a next-generation sequencing-based microsatellite instability assay (MSI NGS) for solid tumor testing | SITC's 33rd Annual Meeting (2018) | 2018 | sitcs-33rd-annual-meeting-2018 | msi | solid-tumors | analytical-validation | 2018 |
| Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-Small Cell Lung Cancer | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | pd-l1-ihc | non-small-cell-lung-cancer | cell-proliferation patient-survival | 2018 |
| Combination immunotherapy selection for non-PD-1 axis driven tumors | 2018 ASCO Annual Meeting | 2018 | 2018-asco-annual-meeting | rnaseq | solid-tumors | immune-profile | 2018 |
| Combination immunotherapy selection for PD-1 axis driven tumors | 2018 ASCO Annual Meeting | 2018 | 2018-asco-annual-meeting | rnaseq | solid-tumors | immune-profile | 2018 |
| PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab | OncoImmunology | 2018 | oncoimmunology | msi pd-l1-ihc rnaseq tmb | urothelial-carcinoma | immune-profile patient-response pd-l2 | 2018 |
| Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden | Journal for ImmunoTherapy of Cancer | 2018 | journal-for-immunotherapy-of-cancer | msi pd-l1-ihc rnaseq tmb | melanoma | patient-survival tumor-inflammation | 2018 |
| Chemokine expression signatures in infiltrated vs non-infiltrated tumors | AACR Annual Meeting 2018 | 2018 | aacr-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | solid-tumors | chemokines infiltrated-tumors tumor-infiltrating-lymphocytes | 2018 |
| PD-L1 driven excluded phenotype in melanoma | AACR Annual Meeting 2018 | 2018 | aacr-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | melanoma | cd8 excluded-phenotype | 2018 |
| Predicting Response: PD-L1 Biomarker Testing by IHC and RNA-seq | AACR Annual Meeting 2018 | 2018 | aacr-annual-meeting-2018 | msi pd-l1-ihc rnaseq tmb | solid-tumors | patient-response pd-l1 | 2018 |
| Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint Inhibition | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | msi pd-l1-ihc rnaseq tmb | solid-tumors | cd8 patient-response | 2018 |
| Comprehensive Immune and Mutational Profile of Melanoma | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | oa | melanoma | immune-profile mutational-profile | 2018 |
| CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | oa | melanoma | ctla4 patient-response | 2018 |
| Lung Cancer Mutational Profile Correlates with Immune Profile | ASCO-SITC Clinical Immuno-Oncology Symposium - 2018 | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | msi pd-l1-ihc rnaseq tmb | lung-cancer | immune-profile mutational-profile | 2018 |
| Overexpression of Immunotherapeutic Targets in the Immune Desert Phenotype | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-desert immune-profile | 2017 |
| Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠ | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-profile | 2017 |
| The Immune-Excluded Phenotype Beyond Colorectal Cancer | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | cd8 excluded-phenotype | 2017 |
| Secondary Immunotherapeutic Targets In Inflamed Tumors | SITC's 32nd Annual Meeting (2017) | 2017 | sitcs-32nd-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | immune-profile tumor-inflammation | 2017 |
| Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors | The Journal of Molecular Diagnostics | 2017 | the-journal-of-molecular-diagnostics | msi pd-l1-ihc rnaseq tmb | solid-tumors | analytical-validation | 2017 |
| Algorithmic Prediction of Response to Checkpoint Inhibitors | 2017 ASCO Annual Meeting | 2017 | 2017-asco-annual-meeting | rnaseq | solid-tumors | patient-response predicitve-algorithm | 2017 |
| The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint Inhibitors | Immunology 2017 | 2017 | immunology-2017 | msi pd-l1-ihc rnaseq tmb | melanoma | patient-response tumor-inflammation | 2017 |
| The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint Inhibitors | Immunology 2017 | 2017 | immunology-2017 | msi pd-l1-ihc rnaseq tmb | non-small-cell-lung-cancer | patient-response tumor-inflammation | 2017 |
| Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification | AACR Annual Meeting 2017 | 2017 | aacr-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | specimen-characteristics validation | 2017 |
| NGS reveals specimen characteristics have minimal impact on immune gene expression signature | AACR Annual Meeting 2017 | 2017 | aacr-annual-meeting-2017 | rnaseq | specimen-characteristics validation | 2017 | |
| Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient | AACR Annual Meeting 2017 | 2017 | aacr-annual-meeting-2017 | msi pd-l1-ihc rnaseq tmb | solid-tumors | specimen-characteristics validation | 2017 |
| Analytical Validation of an Immune Response Assay for Classifying Solid Tumors | 2017 ASCO Annual Meeting | 2017 | 2017-asco-annual-meeting | msi pd-l1-ihc rnaseq tmb | analytical-validation | 2017 | |
| Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing | Oncotarget | 2016 | oncotarget | msi pd-l1-ihc rnaseq tmb | solid-tumors | comparator-study specimen-characteristics validation | 2016 |
| An Algorithmic Approach to Cancer Immune Profiling | SITC's 31st Annual Meeting (2016) | 2016 | sitcs-31st-annual-meeting-2016 | msi pd-l1-ihc rnaseq tmb | solid-tumors | patient-response predicitve-algorithm | 2016 |
| Validation of a Custom RNA-Seq Approach to Cancer Immune Profiling | SITC's 31st Annual Meeting (2016) | 2016 | sitcs-31st-annual-meeting-2016 | msi pd-l1-ihc rnaseq tmb | solid-tumors | comparator-study specimen-characteristics validation | 2016 |